These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19147763)

  • 1. Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib.
    Ma J; Waxman DJ
    Clin Cancer Res; 2009 Jan; 15(2):578-88. PubMed ID: 19147763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenesis enhances intratumoral drug retention.
    Ma J; Chen CS; Blute T; Waxman DJ
    Cancer Res; 2011 Apr; 71(7):2675-85. PubMed ID: 21447737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.
    Ma J; Waxman DJ
    Mol Cancer Ther; 2008 Jan; 7(1):79-89. PubMed ID: 18202011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.
    Doloff JC; Waxman DJ
    Cancer Res; 2012 Mar; 72(5):1103-15. PubMed ID: 22237627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
    Zhang K; Waxman DJ
    Mol Cancer Ther; 2013 May; 12(5):787-98. PubMed ID: 23635653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo.
    He Q; Gao J; Ge S; Wang T; Li Y; Peng Z; Li Y; Shen L
    J Cancer Res Clin Oncol; 2014 Sep; 140(9):1575-83. PubMed ID: 24804814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
    Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R
    Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.
    Canu B; Fioravanti A; Orlandi P; Di Desidero T; Alì G; Fontanini G; Di Paolo A; Del Tacca M; Danesi R; Bocci G
    Neoplasia; 2011 Mar; 13(3):217-29. PubMed ID: 21390185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.
    Eswaraka J; Giddabasappa A; Han G; Lalwani K; Eisele K; Feng Z; Affolter T; Christensen J; Li G
    BMC Cancer; 2014 Oct; 14():742. PubMed ID: 25277255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.
    Manley E; Waxman DJ
    J Pharmacol Exp Ther; 2013 Feb; 344(2):368-77. PubMed ID: 23192656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    Takahashi N; Haba A; Matsuno F; Seon BK
    Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
    Takahashi H; Ojima H; Shimizu H; Furuse J; Furukawa H; Shibata T
    Jpn J Clin Oncol; 2014 Jun; 44(6):570-8. PubMed ID: 24755544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine.
    Doloff JC; Khan N; Ma J; Demidenko E; Swartz HM; Jounaidi Y
    Curr Cancer Drug Targets; 2009 Sep; 9(6):777-88. PubMed ID: 19754361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
    Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
    Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor.
    Kelly RJ; Rixe O
    Target Oncol; 2009 Dec; 4(4):297-305. PubMed ID: 19876699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic effect of axitinib and 5-FU in nude mice bearing human colon cancer xenograft].
    Zhao J; Zhao T; Xie F; He B
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jun; 32(6):890-3. PubMed ID: 22699078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.
    Chow A; Wong A; Francia G; Man S; Kerbel RS; Emmenegger U
    Invest New Drugs; 2014 Feb; 32(1):47-59. PubMed ID: 23728939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
    McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
    Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy.
    Choi JY; Ramasamy T; Kim SY; Kim J; Ku SK; Youn YS; Kim JR; Jeong JH; Choi HG; Yong CS; Kim JO
    Acta Biomater; 2016 Jul; 39():94-105. PubMed ID: 27163403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.